Abstract
The in vitro activity of BMY-28100 was compared with that of four other oral cephalosporins against gram-positive cocci,Branhamella catarrhalis and Haemophilus influenzae.BMY-28100 showed 5–20 times better activity against staphylococci and streptococci. Methicillin-resistant staphylococci and enterococci were resistant to the drug.Branhamella catarrhalis and Haemophilus influenzae strains were moderately susceptible. Time-kill curve studies showed BMY-28100 to be equally as active as benzylpenicillin, amoxycillin, flucloxacillin and cefaclor. By virtue of its in vitro spectrum, BMY-28100 can be considered a potentially useful agent for treatment of respiratory tract infections.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A. Villanova, PA, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kayser, F.H. Comparative antibacterial activity of the new oral cephalosporin BMY-28100. Eur. J. Clin. Microbiol. 6, 309–312 (1987). https://doi.org/10.1007/BF02017621
Issue Date:
DOI: https://doi.org/10.1007/BF02017621